 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  and  ;

or a pharmaceutically acceptable salt thereof.

[0002b] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002c] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002d] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002e] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002f] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002g] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002h] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002i] In another aspect, the present disclosure refers to a compound having a structure



or pharmaceutically acceptable salt thereof.

[0002j] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002k] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002l] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002m] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002n] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002o] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002p] In another aspect, the present disclosure refers to a compound having a structure



or a pharmaceutically acceptable salt thereof.

[0002q] In another aspect, the present disclosure refers to a pharmaceutical composition comprising the compound as described herein and a pharmaceutically acceptable excipient.

[0002r] In another aspect, the present disclosure refers to an *in vitro* method of inhibiting KRAS G12C in a cell, comprising contacting the cell with the compound as described herein or the composition as described herein.

[0002s] In another aspect, the present disclosure refers to the use of the compound as described herein or the composition as described herein in the manufacture of a medicament for treating cancer in a subject.

[0003] Provided herein are compound having a structure of formula (I)



(I)

wherein

E^1 and E^2 are each independently N or CR^1;

R^1 is independently H, hydroxy, $C_{1–6}$alkyl, $C_{1–6}$haloalkyl, C_{1-6}alkoxy, NH-C_{1-6}alkyl, N(C_{1-6}alkyl)$_2$, cyano, or halo;

R^2 is halo, $C_{1–6}$alkyl, $C_{1–6}$haloalkyl, OR', N(R')$_2$, $C_{2–3}$alkenyl, $C_{2–3}$alkynyl, $C_{0–3}$ alkylene-$C_{3–14}$cycloalkyl, $C_{0–3}$alkylene-$C_{2–14}$heterocycloalkyl, aryl, heteroaryl, $C_{0–3}$ alkylenearyl, or $C_{0–3}$ alkyleneheteroaryl, and each R' is independently H, C_{1-6} alkyl, C_{1-6}haloalkyl, C_{3-14}cycloalkyl, $C_{2–14}$heterocycloalkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, aryl, or heteroaryl, or two R' substituents, together with the nitrogen atom to which they are attached, form a 3-7-membered ring;

R^3 is halo, $C_{1–3}$alkyl, $C_{1–2}$haloalkyl, $C_{1–3}$alkoxy, $C_{3–4}$cycloalkyl, $C_{2–3}$ alkenyl, $C_{2–3}$alkynyl, aryl, or heteroaryl;

R^4 is



;

ring A is a monocyclic 4–7 membered ring or a bicyclic, bridged, fused, or spiro 6–11 membered ring;

L is a bond, C_{1-6}alkylene, -O-$C_{0–5}$alkylene, -S-$C_{0–5}$alkylene, or -NH-$C_{0–5}$ alkylene, and

CLAIMS

What is claimed is:

1. A compound having a structure selected from:

 ,  ,  ,

 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  , and  ;

or a pharmaceutically acceptable salt thereof.

2. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

3. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

4. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

5. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

6. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

7. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

8. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

9. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

10. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

11. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

12. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

13. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

14. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

15. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

16. A compound having a structure 

or a pharmaceutically acceptable salt thereof.

17. The compound of any one of claims 1-16 in the form of a pharmaceutically acceptable salt.

18. A pharmaceutical composition comprising the compound of any one of claims 1-17 and a pharmaceutically acceptable excipient.

19. An *in vitro* method of inhibiting KRAS G12C in a cell, comprising contacting the cell with the compound of any one of claims 1-17 or the composition of claim 18.

20. Use of the compound of any one of claims 1-17 or the composition of claim 18 in the manufacture of a medicament for treating cancer in a subject.

21. The use of claim 20, wherein the cancer is lung cancer, pancreatic cancer, or colorectal cancer.

22. The use of claim 20, wherein the cancer is lung cancer.

23. The use of claim 22, wherein the lung cancer is non-small cell lung cancer.

24. The use of claim 20, wherein the cancer is pancreatic cancer.

25. The use of claim 20, wherein the cancer is colorectal cancer.

26. The use of any one of claims 20-25, wherein the cancer is mediated by a KRAS G12C mutation.